Platelet Mediated Inflammation in Coronary Artery Disease with Type 2 Diabetes Patients

References

• Adela R, Banerjee SK. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res. 2015;2015:490842. doi:10.1155/2015/490842
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
   PubMed Web of Science ®Google Scholar
• Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin. 2014;32(3):439–455. doi:10.1016/j.ccl.2014.04.001
   PubMed Web of Science ®Google Scholar
• Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):1–14. doi:10.1186/s12933-018-0762-4
   PubMed Web of Science ®Google Scholar
• Nam H, Cho Y, Lim J, et al. Functional status of immune cells in patients with long‐lasting type 2 diabetes mellitus. Clin Exp Immunol. 2018;194(1):125–136. doi:10.1111/cei.13187
   PubMed Web of Science ®Google Scholar
• Nagareddy PR, Murphy AJ, Stirzaker RA, et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 2013;17:695–708. doi:10.1016/j.cmet.2013.04.001
   PubMed Web of Science ®Google Scholar
• Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat Rev Immunol. 2019;19(12):734–746. doi:10.1038/s41577-019-0213-9
   PubMed Web of Science ®Google Scholar
• Adela R, Reddy PNC, Ghosh TS, et al. Serum protein signature of coronary artery disease in type 2 diabetes mellitus. J Transl Med. 2019;17(1):1–17. doi:10.1186/s12967-018-1755-5
   PubMedGoogle Scholar
• Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood. 2014;123(18):2759–2767. doi:10.1182/blood-2013-11-462432
   PubMed Web of Science ®Google Scholar
• Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):1–17. doi:10.1186/s12933-018-0763-3
   PubMedGoogle Scholar
• Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011;2011:1–14. doi:10.1155/2011/742719
   Web of Science ®Google Scholar
• Israels SJ, McNicol A, Dean HJ, Cognasse F, Sellers EA. Markers of platelet activation are increased in adolescents with type 2 diabetes. Diabetes Care. 2014;37(8):2400–2403. doi:10.2337/dc13-2718
   PubMed Web of Science ®Google Scholar
• Pretorius L, Thomson GJ, Adams RC, Nell TA, Laubscher WA, Pretorius E. Platelet activity and hypercoagulation in type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):1–11. doi:10.1186/s12933-018-0783-z
   PubMedGoogle Scholar
• Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015;114(09):449–458. doi:10.1160/TH14-12-1067
   PubMedGoogle Scholar
• Rossaint J, Margraf A, Zarbock A. Role of platelets in leukocyte recruitment and resolution of inflammation. Front Immunol. 2018;9:2712. doi:10.3389/fimmu.2018.02712
   PubMed Web of Science ®Google Scholar
• Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13. doi:10.1093/nar/gkn923
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5(4):444. doi:10.4239/wjd.v5.i4.444
   PubMedGoogle Scholar
• Pedicino D, Liuzzo G, Trotta F, et al. Adaptive immunity, inflammation, and cardiovascular complications in type 1 and type 2 diabetes mellitus. J Diabetes Res. 2013;2013:1–11. doi:10.1155/2013/184258
   Web of Science ®Google Scholar
• Madhumitha H, Mohan V, Deepa M, Babu S, Aravindhan V. Increased Th1 and suppressed Th2 serum cytokine levels in subjects with diabetic coronary artery disease. Cardiovasc Diabetol. 2014;13(1):1–8. doi:10.1186/1475-2840-13-1
   PubMedGoogle Scholar
• Pretorius E. Platelets as potent signaling entities in type 2 diabetes mellitus. Trends Endocrinol Metab. 2019;30(8):532–545. doi:10.1016/j.tem.2019.05.003
   PubMed Web of Science ®Google Scholar
• Shantsila E, Tapp LD, Wrigley BJ, et al. Monocyte subsets in coronary artery disease and their associations with markers of inflammation and fibrinolysis. Atherosclerosis. 2014;234(1):4–10. doi:10.1016/j.atherosclerosis.2014.02.009
   PubMed Web of Science ®Google Scholar
• Kapellos TS, Bonaguro L, Gemünd I, et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. 2019;10:2035. doi:10.3389/fimmu.2019.02035
   PubMed Web of Science ®Google Scholar
• Seifarth C, Hinkmann C, Hahn E-G, Lohmann T, Harsch I. Reduced frequency of peripheral dendritic cells in type 2 diabetes. Exp Clin Endocrinol Diabetes. 2008;116(03):162–166. doi:10.1055/s-2007-990278
   PubMedGoogle Scholar
• Van Vre EA, Hoymans VY, Bult H, et al. Decreased number of circulating plasmacytoid dendritic cells in patients with atherosclerotic coronary artery disease. Coron Artery Dis. 2006;17(3):243–248. doi:10.1097/00019501-200605000-00007
   PubMed Web of Science ®Google Scholar
• Zernecke A. Dendritic cells in atherosclerosis: evidence in mice and humans. Arterioscler Thromb Vasc Biol. 2015;35(4):763–770. doi:10.1161/ATVBAHA.114.303566
   PubMed Web of Science ®Google Scholar
• Gkaliagkousi E, Gavriilaki E, Yiannaki E, et al. Platelet activation in essential hypertension during exercise: pre-and post-treatment changes with an angiotensin II receptor blocker. Am J Hypertens. 2014;27(4):571–578. doi:10.1093/ajh/hpt153
   PubMed Web of Science ®Google Scholar
• Gkaliagkousi E, Corrigall V, Becker S, et al. Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. Eur Heart J. 2009;30(24):3048–3054. doi:10.1093/eurheartj/ehp330
   PubMed Web of Science ®Google Scholar
• Goubareva I, Gkaliagkousi E, Shah A, Queen L, Ritter J, Ferro A. Age decreases nitric oxide synthesis and responsiveness in human platelets and increases formation of monocyte–platelet aggregates. Cardiovasc Res. 2007;75(4):793–802. doi:10.1016/j.cardiores.2007.05.021
   PubMed Web of Science ®Google Scholar
• Gupta M, Brister S, Verma S. Is South Asian ethnicity an independent cardiovascular risk factor? Can J Cardiol. 2006;22(3):193–197. doi:10.1016/s0828-282x(06)70895-9
   PubMed Web of Science ®Google Scholar
• Martins PA, van Gils JM, Mol A, Hordijk PL, Zwaginga JJ. Platelet binding to monocytes increases the adhesive properties of monocytes by up‐regulating the expression and functionality of β1 and β2 integrins. J Leukoc Biol. 2006;79(3):499–507. doi:10.1189/jlb.0605318
   PubMed Web of Science ®Google Scholar
• Page C, Pitchford S. Neutrophil and platelet complexes and their relevance to neutrophil recruitment and activation. Int Immunopharmacol. 2013;17(4):1176–1184. doi:10.1016/j.intimp.2013.06.004
   PubMed Web of Science ®Google Scholar
• Passacquale G, Vamadevan P, Pereira L, Hamid C, Corrigall V, Ferro A. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One. 2011;6(10):e25595. doi:10.1371/journal.pone.0025595
   PubMed Web of Science ®Google Scholar
• Gkaliagkousi E, Nikolaidou B, Gavriilaki E, et al. Increased erythrocyte-and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus. Diab Vasc Dis Res. 2019;16(5):458–465. doi:10.1177/1479164119844691
   PubMed Web of Science ®Google Scholar
• Gkaliagkousi E, Gavriilaki E, Yiannaki E, et al. Platelet microvesicles are associated with the severity of coronary artery disease: comparison between peripheral and coronary circulation. J Thromb Thrombolysis. 2021;51(4):1138–1143. doi:10.1007/s11239-020-02302-5
   PubMed Web of Science ®Google Scholar
• Lazaridis A, Gavriilaki E, Nikolaidou B, et al. A study of endothelial and platelet microvesicles across different hypertension phenotypes. J Hum Hypertens. 2021;1–9. doi:10.1038/s41371-021-00531-6.
   Web of Science ®Google Scholar
• Yun S-H, Sim E-H, Goh R-Y, Park J-I, Han J-Y. Platelet activation: the mechanisms and potential biomarkers. Biomed Res Int. 2016;2016:1–5. doi:10.1155/2016/9060143
   Web of Science ®Google Scholar
• Herder C, Haastert B, Müller-Scholze S, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes. 2005;54(suppl2):S11–S17. doi:10.2337/diabetes.54.suppl_2.s11
   PubMedGoogle Scholar
• Araújo LS, da Silva MV, da Silva CA, et al. Analysis of serum inflammatory mediators in type 2 diabetic patients and their influence on renal function. PLoS One. 2020;15(3):e0229765. doi:10.1371/journal.pone.0229765
   PubMed Web of Science ®Google Scholar
• Lam FW, Vijayan KV, Rumbaut RE. Platelets and their interactions with other immune cells. Compr Physiol. 2015;5(3):1265. doi:10.1002/cphy.c140074
   PubMed Web of Science ®Google Scholar
• Min X, Lu M, Tu S, et al. Serum cytokine profile in relation to the severity of coronary artery disease. Biomed Res Int. 2017;2017:1–9. doi:10.1155/2017/4013685
   Web of Science ®Google Scholar
• Kumari R, Kumar S, Ahmad MK, et al. TNF-α/IL-10 ratio: an independent predictor for coronary artery disease in North Indian population. Diabetes Metab Syndr. 2018;12(3):221–225. doi:10.1016/j.dsx.2017.09.006
   PubMed Web of Science ®Google Scholar
• Shirai T, Nazarewicz RR, Wallis BB, et al. The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. J Exp Med. 2016;213(3):337–354. doi:10.1084/jem.20150900
   PubMed Web of Science ®Google Scholar
• Ding R, Gao W, Ostrodci DH, et al. Effect of interleukin-2 level and genetic variants on coronary artery disease. Inflammation. 2013;36(6):1225–1231. doi:10.1007/s10753-013-9659-2
   PubMed Web of Science ®Google Scholar
• Shintani Y, Ito T, Fields L, et al. IL-4 as a repurposed biological drug for myocardial infarction through augmentation of reparative cardiac macrophages: proof-of-concept data in mice. Sci Rep. 2017;7(1):1–14. doi:10.1038/s41598-017-07328-z
   PubMedGoogle Scholar
• Yuan S, Lin A, He Q-Q, Burgess S, Larsson SC. Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its subtypes: a two-sample Mendelian randomization study. Int J Cardiol. 2020;313:99–104. doi:10.1016/j.ijcard.2020.03.053
   PubMed Web of Science ®Google Scholar
• Zhang S, Gao Y, Huang J. Interleukin-8 gene− 251 A/T (rs4073) polymorphism and coronary artery disease risk: a meta-analysis. Med Sci Monit. 2019;25:1645. doi:10.12659/MSM.913591
   PubMed Web of Science ®Google Scholar
• Podolec J, Kopeć G, Niewiara MK, et al. Chemokine RANTES is increased at early stages of atherosclerosis severity. J Physiol Pharmacol. 2016;67(2):321–328.
   PubMed Web of Science ®Google Scholar
• Pordel S, Sajedi Khanian M, Karimi MH, Nikoo H, Doroudchi M. Plasma CXCL 1 levels and TRAF 3 IP 2 variants in patients with myocardial infarction. J Clin Lab Anal. 2018;32(6):e22402. doi:10.1002/jcla.22402
   PubMed Web of Science ®Google Scholar
• Trøseid M, Seljeflot I, Arnesen H. The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol. 2010;9(1):1–8. doi:10.1186/1475-2840-9-11
   PubMedGoogle Scholar
• Suchanek H, Myśliwska J, Siebert J, et al. High serum interleukin-18 concentrations in patients with coronary artery disease and type 2 diabetes mellitus. Eur Cytokine Netw. 2005;16(3):177–185.
   PubMed Web of Science ®Google Scholar
• Lin J, Kakkar V, Lu X. Impact of MCP-1 in atherosclerosis. Curr Pharm Des. 2014;20(28):4580–4588. doi:10.2174/1381612820666140522115801
   PubMed Web of Science ®Google Scholar
• Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A. 2003;100(12):7265–7270. doi:10.1073/pnas.1133870100
   PubMed Web of Science ®Google Scholar
• Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J Cell Biol. 2001;154(3):485–490. doi:10.1083/jcb.200105058
   PubMed Web of Science ®Google Scholar
• Brown GT, McIntyre TM. Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1β–rich microparticles. J Immunol. 2011;186(9):5489–5496. doi:10.4049/jimmunol.1001623
   PubMed Web of Science ®Google Scholar
• Hottz ED, Monteiro APT, Bozza FA, Bozza PT. Inflammasome in platelets: allying coagulation and inflammation in infectious and sterile diseases? Mediators Inflamm. 2015;2015:1–7. doi:10.1155/2015/435783
   Web of Science ®Google Scholar
• Rolfes V, Ribeiro LS, Hawwari I, et al. Platelets fuel the inflammasome activation of innate immune cells. Cell Rep. 2020;31(6):107615. doi:10.1016/j.celrep.2020.107615
   PubMed Web of Science ®Google Scholar
• Scherr C, Albuquerque DC, Pozzan R, et al. Role of interleukin-18 and the thrombus precursor protein in coronary artery disease. Arq Bras Cardiol. 2020;114(4):692–698. doi:10.36660/abc.20190176
   PubMed Web of Science ®Google Scholar
• Kral JB, Schrottmaier WC, Salzmann M, Assinger A. Platelet interaction with innate immune cells. Transfus Med Hemother. 2016;43(2):78–88. doi:10.1159/000444807
   PubMed Web of Science ®Google Scholar
• Kojok K, El-Kadiry AE-H, Merhi Y. Role of NF-κB in platelet function. Int J Mol Sci. 2019;20(17):4185. doi:10.3390/ijms20174185
   PubMed Web of Science ®Google Scholar
• Gleissner CA, von Hundelshausen P, Ley K. Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol. 2008;28(11):1920–1927. doi:10.1161/ATVBAHA.108.169417
   PubMed Web of Science ®Google Scholar
• Liu D, Cao Y, Zhang X, et al. Chemokine CC-motif ligand 2 participates in platelet function and arterial thrombosis by regulating PKCα-P38MAPK-HSP27 pathway. Biochim Biophys Acta Mol Basis Dis. 2018;1864(9):2901–2912. doi:10.1016/j.bbadis.2018.05.025
   PubMed Web of Science ®Google Scholar